Which has preferable valuation & earnings, AAPG or ANL?

Adlai Nortye has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 21.04 -$177.71M N/A N/A Adlai Nortye $5M 75.92 -$35.53M N/A N/A

Is AAPG or ANL more profitable?

Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Adlai Nortye N/A N/A N/A

Which has stronger valuation and earnings, ANL or DMRA?

Adlai Nortye has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 75.92 -$35.53M N/A N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is ANL or DMRA more profitable?

Adlai Nortye's return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Which has better earnings & valuation, ANL or MAZE?

Adlai Nortye has higher earnings, but lower revenue than Maze Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 75.92 -$35.53M N/A N/A Maze Therapeutics $167.50M 10.33 -$131.12M -$2.53 N/A

Is ANL or MAZE more profitable?

Adlai Nortye's return on equity of 0.00% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Maze Therapeutics N/A -36.62% -31.78%

Which has better valuation and earnings, ANL or AKTS?

Adlai Nortye has higher earnings, but lower revenue than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 75.92 -$35.53M N/A N/A Aktis Oncology $6.50M 260.92 -$63.73M -$0.38 N/A

Is ANL or AKTS more profitable?

Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Aktis Oncology N/A N/A N/A

Which has stronger earnings & valuation, VIR or ANL?

Adlai Nortye has lower revenue, but higher earnings than Vir Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vir Biotechnology $68.56M 24.70 -$437.99M -$3.13 N/A Adlai Nortye $5M 75.92 -$35.53M N/A N/A

Adlai Nortye (ANL) Competitors

$9.49 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$9.59 +0.10 (+1.04%)

As of 07/2/2026 07:56 PM Eastern

Compare

ANL vs. AAPG, DMRA, MAZE, AKTS, and VIR

Should you buy Adlai Nortye stock or one of its competitors? MarketBeat compares Adlai Nortye with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adlai Nortye include Ascentage Pharma Group International (AAPG), Damora Therapeutics, Inc. Common Stock (DMRA), Maze Therapeutics (MAZE), Aktis Oncology (AKTS), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.

How does Adlai Nortye compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Ascentage Pharma Group International had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Ascentage Pharma Group International and 0 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.00 beat Ascentage Pharma Group International's score of -0.35 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascentage Pharma Group International	Neutral
Adlai Nortye	Neutral

Ascentage Pharma Group International currently has a consensus target price of $46.43, indicating a potential upside of 150.97%. Adlai Nortye has a consensus target price of $24.25, indicating a potential upside of 155.53%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Adlai Nortye has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	21.04	-$177.71M	N/A	N/A
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A

35.2% of Adlai Nortye shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ascentage Pharma Group International has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Adlai Nortye	N/A	N/A	N/A

Summary

Adlai Nortye beats Ascentage Pharma Group International on 6 of the 11 factors compared between the two stocks.

How does Adlai Nortye compare to Damora Therapeutics, Inc. Common Stock?

Adlai Nortye (NASDAQ:ANL) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 1 mentions for Damora Therapeutics, Inc. Common Stock and 0 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.00 equaled Damora Therapeutics, Inc. Common Stock'saverage media sentiment score.

Company	Overall Sentiment
Adlai Nortye	Neutral
Damora Therapeutics, Inc. Common Stock	Neutral

Adlai Nortye has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Adlai Nortye currently has a consensus price target of $24.25, suggesting a potential upside of 155.53%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.43, suggesting a potential upside of 41.52%. Given Adlai Nortye's higher possible upside, research analysts clearly believe Adlai Nortye is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Adlai Nortye's return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Adlai Nortye has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Summary

Adlai Nortye and Damora Therapeutics, Inc. Common Stock tied by winning 6 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to Maze Therapeutics?

Adlai Nortye (NASDAQ:ANL) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 155.53%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 111.13%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Maze Therapeutics had 6 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Maze Therapeutics and 0 mentions for Adlai Nortye. Maze Therapeutics' average media sentiment score of 0.02 beat Adlai Nortye's score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adlai Nortye	Neutral
Maze Therapeutics	Neutral

Adlai Nortye's return on equity of 0.00% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Maze Therapeutics	N/A	-36.62%	-31.78%

35.2% of Adlai Nortye shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Adlai Nortye has higher earnings, but lower revenue than Maze Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A
Maze Therapeutics	$167.50M	10.33	-$131.12M	-$2.53	N/A

Adlai Nortye has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Summary

Maze Therapeutics beats Adlai Nortye on 8 of the 14 factors compared between the two stocks.

How does Adlai Nortye compare to Aktis Oncology?

Adlai Nortye (NASDAQ:ANL) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Adlai Nortye has higher earnings, but lower revenue than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A
Aktis Oncology	$6.50M	260.92	-$63.73M	-$0.38	N/A

Adlai Nortye currently has a consensus target price of $24.25, indicating a potential upside of 155.53%. Aktis Oncology has a consensus target price of $34.00, indicating a potential upside of 7.05%. Given Adlai Nortye's higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Aktis Oncology had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Aktis Oncology and 0 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.00 equaled Aktis Oncology'saverage media sentiment score.

Company	Overall Sentiment
Adlai Nortye	Neutral
Aktis Oncology	Neutral

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Adlai Nortye on 7 of the 10 factors compared between the two stocks.

How does Adlai Nortye compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Adlai Nortye has lower revenue, but higher earnings than Vir Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	24.70	-$437.99M	-$3.13	N/A
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A

Vir Biotechnology currently has a consensus price target of $20.88, suggesting a potential upside of 107.92%. Adlai Nortye has a consensus price target of $24.25, suggesting a potential upside of 155.53%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Vir Biotechnology had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Vir Biotechnology and 0 mentions for Adlai Nortye. Vir Biotechnology's average media sentiment score of 1.24 beat Adlai Nortye's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Vir Biotechnology	Positive
Adlai Nortye	Neutral

Vir Biotechnology has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Adlai Nortye has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Adlai Nortye's return on equity of 0.00% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Adlai Nortye	N/A	N/A	N/A

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Vir Biotechnology beats Adlai Nortye on 9 of the 15 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$379.60M	$3.76B	$7.18B	$12.46B
Dividend Yield	N/A	2.16%	2.67%	6.49%
P/E Ratio	N/A	21.43	27.75	24.70
Price / Sales	75.92	324.82	533.82	98.65
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-45.19	8.66	10.96	6.46
Net Income	-$35.53M	$23.81M	$3.57B	$337.01M
7 Day Performance	-5.10%	3.39%	2.11%	1.70%
1 Month Performance	-13.73%	6.15%	2.80%	0.68%
1 Year Performance	506.00%	62.61%	33.39%	23.94%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	1.5454 of 5 stars	$9.49 flat	$24.25 +155.5%	+506.0%	$379.60M	$5M	N/A	127	Gap Up High Trading Volume
AAPG Ascentage Pharma Group International	4.5258 of 5 stars	$17.96 +2.3%	$46.43 +158.5%	-56.8%	$1.68B	$82.10M	N/A	600	High Trading Volume
DMRA Damora Therapeutics, Inc. Common Stock	2.9925 of 5 stars	$27.09 +4.2%	$42.43 +56.6%	+769.0%	$1.67B	N/A	N/A	40	Gap Down
MAZE Maze Therapeutics	2.0049 of 5 stars	$29.81 -0.1%	$66.00 +121.4%	+171.8%	$1.65B	$167.50M	N/A	121	News Coverage Insider Trade Gap Down
AKTS Aktis Oncology	1.0071 of 5 stars	$30.89 -4.2%	$34.00 +10.1%	N/A	$1.65B	$6.50M	N/A	76	Lockup Expiration

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. AAPG, DMRA, MAZE, AKTS, and VIR

How does Adlai Nortye compare to Ascentage Pharma Group International?

Summary

How does Adlai Nortye compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Adlai Nortye compare to Maze Therapeutics?

Summary

How does Adlai Nortye compare to Aktis Oncology?

Summary

How does Adlai Nortye compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. AAPG, DMRA, MAZE, AKTS, and VIR

How does Adlai Nortye compare to Ascentage Pharma Group International?

Does the media favor AAPG or ANL?

Do analysts prefer AAPG or ANL?

Which has preferable valuation & earnings, AAPG or ANL?

Do institutionals and insiders hold more shares of AAPG or ANL?

Which has more risk & volatility, AAPG or ANL?

Is AAPG or ANL more profitable?

Summary

How does Adlai Nortye compare to Damora Therapeutics, Inc. Common Stock?

Does the media favor ANL or DMRA?

Which has more risk and volatility, ANL or DMRA?

Do insiders & institutionals believe in ANL or DMRA?

Do analysts rate ANL or DMRA?

Is ANL or DMRA more profitable?

Which has stronger valuation and earnings, ANL or DMRA?

Summary

How does Adlai Nortye compare to Maze Therapeutics?

Do analysts rate ANL or MAZE?

Does the media favor ANL or MAZE?

Is ANL or MAZE more profitable?

Do institutionals and insiders believe in ANL or MAZE?

Which has better earnings & valuation, ANL or MAZE?

Which has more risk & volatility, ANL or MAZE?

Summary

How does Adlai Nortye compare to Aktis Oncology?

Which has better valuation and earnings, ANL or AKTS?

Do analysts rate ANL or AKTS?

Does the media prefer ANL or AKTS?

Do insiders & institutionals believe in ANL or AKTS?

Is ANL or AKTS more profitable?

Summary

How does Adlai Nortye compare to Vir Biotechnology?

Which has stronger earnings & valuation, VIR or ANL?

Do analysts recommend VIR or ANL?

Does the media refer more to VIR or ANL?

Which has more risk & volatility, VIR or ANL?

Is VIR or ANL more profitable?

Do insiders and institutionals believe in VIR or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools